↓ Skip to main content

Economic comparison of capecitabine + oxaliplatin and 5-fluorouracil + oxaliplatin in the adjuvant treatment of colon cancer.

Overview of attention for article published in Cancer Management and Research, April 2012
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
17 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Economic comparison of capecitabine + oxaliplatin and 5-fluorouracil + oxaliplatin in the adjuvant treatment of colon cancer.
Published in
Cancer Management and Research, April 2012
DOI 10.2147/cmar.s29267
Pubmed ID
Abstract

Colorectal cancer is one of the most frequent and lethal cancers. The aim of this study was to analyze the costs relating to treatment of colorectal cancer between Xelox and Folfox-4 at a regional level according to the clinical experience at an Italian hospital in Lombardy.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
France 1 6%
Unknown 16 94%

Demographic breakdown

Readers by professional status Count As %
Student > Master 6 35%
Other 3 18%
Student > Bachelor 2 12%
Researcher 2 12%
Student > Postgraduate 2 12%
Other 2 12%
Readers by discipline Count As %
Medicine and Dentistry 9 53%
Agricultural and Biological Sciences 2 12%
Biochemistry, Genetics and Molecular Biology 1 6%
Nursing and Health Professions 1 6%
Social Sciences 1 6%
Other 2 12%
Unknown 1 6%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 November 2013.
All research outputs
#6,939,498
of 12,073,561 outputs
Outputs from Cancer Management and Research
#143
of 380 outputs
Outputs of similar age
#57,934
of 112,920 outputs
Outputs of similar age from Cancer Management and Research
#13
of 20 outputs
Altmetric has tracked 12,073,561 research outputs across all sources so far. This one is in the 40th percentile – i.e., 40% of other outputs scored the same or lower than it.
So far Altmetric has tracked 380 research outputs from this source. They receive a mean Attention Score of 3.1. This one has gotten more attention than average, scoring higher than 58% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 112,920 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one is in the 35th percentile – i.e., 35% of its contemporaries scored the same or lower than it.